Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.2 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - English - Ministry of Health

david margalit & co.ltd - octreotide as acetate - solution for injection - octreotide as acetate 0.5 mg/ml - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.octreotide bendalis treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome. - vipomas . - glucagonomas . - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . - grfomas. - octreotide bendalis is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml - solution for injection - 100 mcg/ml - active: octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml - solution for injection - 50 mcg/ml - active: octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml - solution for injection - 500 mcg/ml - active: octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 50 microgram - injection, solution - excipient ingredients: water for injections; sodium chloride; glacial acetic acid; sodium acetate trihydrate - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 100 microgram - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium acetate trihydrate; glacial acetic acid - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 500 microgram - injection, solution - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 100 microgram(s)/millilitre - somatostatin and analogues; octreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 200 microgram(s)/millilitre - somatostatin and analogues; octreotide